Poop pills or tubes: could fecal transplants tame deadly transplant complication?
NCT ID NCT07602751
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving fecal microbiota (from a healthy donor) via a tube or scope into the gut can safely help children and young adults with severe intestinal graft-versus-host disease that hasn't improved with steroids. About 20 participants aged 3 months to 25 years will receive 1 to 3 treatments. The main goal is to check safety, but researchers will also see if it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fecal microbiota transplantation
What this could lead to
If successful, this could offer a new treatment option for severe gut graft-versus-host disease that doesn't respond to steroids.
What could go wrong
This is an early-phase pilot study with only 20 participants, so results may not apply broadly. Risks include infection or complications from the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital
Roma, 00165, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UOC Clinica di Oncoematologia Pediatrica, Azienda Ospedale-Università Padova
Padova, 35128, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••